The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-09. Anything still debated is marked as such rather than presented as settled.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Since June 20, 1979, the FDA has received many questions about Good Laboratory Practice (GLP) regulations (21 CFR 58). The responses to these inquiries are stored in the Dockets Management Branch (HFA-305) and shared with the Agency's Bioresearch Monitoring (BIMO) program managers and district offices to ensure consistency. Consequently, the US FDA published the 1981 Questions & Answers - Good Laboratory Practice Regulations document to consolidate and clarify these responses. This Q&A document categorizes responses by specific GLP provisions to make them more useful for both the FDA headquarters and field offices. The FDA has signed a memorandum of understanding (MOU) with Canada, France, Germany, Italy, Japan, The Netherlands, Sweden, and Switzerland to enhance cooperation on good laboratory practice (GLP) for nonclinical laboratory studies supporting product approvals, aiming to facilitate information exchange and inspections for regulatory oversight. Proposed amendments were published in the Federal Register on August 24, 2016, which aimed to require a comprehensive quality system approach known as a GLP Quality System to enhance the current quality system approach for nonclinical laboratory studies. This system would be mandatory for safety and toxicity studies that support or are intended to support applications or submissions for products regulated by the FDA.
Relatively short fragments of DNA, RNA, and modified oligonucleotides are also synthesised by the solid-phase method. Although oligonucleotides can be synthesised in a flask, they are almost always synthesised on solid phase using a DNA/RNA synthesizer. For a more comprehensive review, see oligonucleotide synthesis. The method of choice is generally phosphoramidite chemistry, developed in the 1980s.
The vertebral column of Tyrannosaurus consisted of ten neck vertebrae, thirteen back vertebrae and five sacral vertebrae. The number of tail vertebrae is unknown and could well have varied between individuals but probably numbered at least forty. Sue was mounted with forty-seven of such caudal vertebrae. The neck of T. rex formed a natural S-shaped curve like that of other theropods. Compared to these, it was exceptionally short, deep and muscular to support the massive head. The second vertebra, the axis, was especially short. The remaining neck vertebrae were weakly opisthocoelous, i.e. with a convex front of the vertebral body and a concave rear. The vertebral bodies had single pleurocoels, pneumatic depressions created by air sacs, on their sides. The vertebral bodies of the torso were robust but with a narrow waist. Their undersides were keeled. The front sides were concave with a deep vertical trough. They had large pleurocoels. Their neural spines had very rough front and rear sides for the attachment of strong tendons. The sacral vertebrae were fused to each other, both in their vertebral bodies and neural spines. They were pneumatized. They were connected to the pelvis by transverse processes and sacral ribs. The tail was heavy and moderately long, in order to balance the massive head and torso and to provide space for massive locomotor muscles that attached to the thighbones. The thirteenth tail vertebra formed the transition point between the deep tail base and the middle tail that was stiffened by a long front articulation processes.
Diagnosis is typically based on medical imaging, such as plain X-rays, and symptoms. In severe OI, signs on medical imaging include abnormalities in all extremities and the spine. As X-rays are often insensitive to the comparatively smaller bone density loss associated with type I OI, DEXA scans may be needed. An OI diagnosis can be confirmed through DNA or collagen protein analysis, but in many cases, the occurrence of bone fractures with little trauma and the presence of other clinical features such as blue sclerae are sufficient for a diagnosis. A skin biopsy can be performed to determine the structure and quantity of type I collagen. While DNA testing can confirm the diagnosis, it cannot absolutely exclude it because not all mutations causing OI are yet known and/or tested for. OI type II is often diagnosed by ultrasound during pregnancy, where already multiple fractures and other characteristic features may be visible. Relative to control, OI cortical bone shows increased porosity, canal diameter, and connectivity in micro-computed tomography. OI can also be detected before birth by using an in vitro genetic testing technique such as amniocentesis.
Sources: en.wikipedia.org
233U is fissile and can be used as a nuclear fuel in the same way as 235U or 239Pu. When 233U undergoes nuclear fission, the neutrons emitted can strike further 232Th nuclei, continuing the cycle. This parallels the uranium fuel cycle in fast breeder reactors where 238U undergoes neutron capture to become 239U, beta decaying to first 239Np and then fissile 239Pu. The fission of 23392U produces 2.48 neutrons on average. One neutron is needed to keep the fission reaction going. For a self-contained continuous breeding cycle, one more neutron is needed to breed a new 23392U atom from the fertile 23290Th. This leaves a margin of 0.45 neutrons (or 18% of the neutron flux) for losses.
== Related compounds == A dual DOR and κ-opioid receptor (KOR) PAM, BMS-986187, derived from BMS-986122, has been developed and is selective for these receptors over the MOR. Another MOR PAM with a simpler synthesis, MS1, was subsequently developed and has shown similar effects to those of BMS-986122. Additionally, ignavine, a natural MOR PAM found in Aconitum, has also been identified. In 2024, ketamine and its metabolites norketamine and hydroxynorketamine (HNK) were identified as highly potent MOR, DOR, and KOR PAMs (active at a concentration of as low as 1 nM). These actions were implicated in their potential antidepressant and analgesic effects.
=== Other effects of shortages === On 14 February, it was announced Festival del Habano, an annual cigar festival, was called off due to "the complex economic situation" caused by the "economic, commercial and financial blockade" by the U.S. On 17 February 2026, it was reported that many collection trucks had been left with empty fuel tanks, causing refuse to pile up on the streets of the capital, Havana, and other cities and towns. Only 44 of Havana's 106 rubbish trucks (approximately 41.5% of them) have been able to keep operating due to the fuel shortages, slowing rubbish collection, as waste piles up on Havana's street corners, the Reuters news agency reported on Monday, citing state-run news outlet Cubadebate. Canadian mining company Sherritt announced that it would pause operations at its mining facility in Moa. State media reported in June that the blockade was damaging the health sector, with locally produced medicines unavailable, kidney dialysis disrupted, and nutrition programs far under capacity. A United Nations human rights report estimated that agricultural output had fallen by 60% in June 2026 due to fuel shortages.
== Society and culture == The term was first used in the 14th century. A fistula plays a central role in William Shakespeare's play All's Well That Ends Well. An arteriovenous fistula is also a main plot point in Richard Fleischer's 1966 film Fantastic Voyage (screenplay by Harry Kleiner), sending the miniaturized submarine inside a patient's body on an unforeseen course.
where A = 0.02939 mPa·s, B = 507.88 K, and C = 149.3 K. Experimentally determined values of the viscosity are also given in the table below. The values at 20 °C are a useful reference: there, the dynamic viscosity is about 1 cP and the kinematic viscosity is about 1 cSt.
Sources: en.wikipedia.org
== Dietary requirements == The Food and Nutrition Board (FNB) of the U.S. Institute of Medicine set Recommended Dietary Allowances (RDAs) for essential amino acids in 2002. For leucine, for adults 19 years and older, 42 mg/kg body weight/day; for isoleucine 19 mg/kg body weight/day; for valine 24 mg/kg body weight/day. For a 70 kg (154 lb) person this equates to 2.9, 1.3 and 1.7 g/day. Diets that meet or exceed the RDA for total protein (0.8 g/kg/day; 56 grams for a 70 kg person), meet or exceed the RDAs for branched-chain amino acids.
== Example of preparing a series of standard solutions == Suppose the concentration of glutamine in an unknown sample needs to be measured. To do so, a series of standard solutions containing glutamine is prepared to create a calibration curve. A table summarizing a method for creating these solutions is shown below:
The country's ten largest self-reported ethnic or cultural origins in 2021 were Canadian (accounting for 15.6 percent of the population), followed by English (14.7%), Irish (12.1%), Scottish (12.1%), French (11.0%), German (8.1%), Chinese (4.7%), Italian (4.3%), Indian (3.7%), and Ukrainian (3.5%). Of the 36.3 million people enumerated in 2021, approximately 25.4 million reported being "White", representing 69.8 percent of the population. The Indigenous population representing 5 percent or 1.8 million people, grew by 9.4 percent compared to the non-Indigenous population, which grew by 5.3 percent from 2016 to 2021. One out of every four Canadians or 26.5 percent of the population belonged to a non-White and non-Indigenous visible minority, the largest of which in 2021 were South Asian (2.6 million people; 7.1%), Chinese (1.7 million; 4.7%), Black (1.5 million; 4.3%), Filipinos (960,000 2.6%), Arabs (690,000; 1.9%), Latin Americans (580,000; 1.6%), Southeast Asians (390,000; 1.1%), West Asians (360,000; 1.0%), Koreans (220,000; 0.6%) and Japanese (99,000; 0.3%). Between 2011 and 2016, the visible minority population rose by 18.4 percent. In 1961, about 300,000 people, less than two percent of Canada's population, were members of visible minority groups. The 2021 census indicated that 8.3 million people, or almost one-quarter (23.0%) of the population, reported themselves as being or having been a landed immigrant or permanent resident in Canada—above the 1921 census previous record of 22.3 percent.
== Further reading == Martin, Christopher S.; Chung, Tammy; Langenbucher, James W. (2017). "Part 1: Defining and Characterizing the Nature and Extent of Substance Use Disorders – Historical and Cultural Perspectives on Substance Use and Substance Use Disorders". In Sher, Kenneth J. (ed.). The Oxford Handbook of Substance Use and Substance Use Disorders: Volume 1. Oxford Library of Psychology. Oxford and New York: Oxford University Press. pp. 27–59. doi:10.1093/oxfordhb/9780199381678.013.001. ISBN 978-0-19-938167-8. LCCN 2016020729. Anthony, James; Barondess, David A.; Radovanovic, Mirjana; Lopez-Quintero, Catalina (2017). "Part 1: Psychiatric Comorbidity – Polydrug Use: Research Topics and Issues". In Sher, Kenneth J. (ed.). The Oxford Handbook of Substance Use and Substance Use Disorders: Volume 2. Oxford Library of Psychology. Oxford and New York: Oxford University Press. pp. 27–59. doi:10.1093/oxfordhb/9780199381708.013.006. ISBN 978-0-19-938170-8. LCCN 2016020729. Hernández-Serrano, Olga; Gras, Maria E.; Font-Mayolas, Sílvia; Sullman, Mark J. M. (2016). "Part VI: Dual and Polydrug Abuse – Chapter 83: Types of Polydrug Usage". In Preedy, Victor R. (ed.). Neuropathology of Drug Addictions and Substance Misuse, Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions. Cambridge, Massachusetts: Academic Press, imprint of Elsevier. pp. 839–849. doi:10.1016/B978-0-12-800634-4.00083-4. ISBN 978-0-12-800634-4.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.